Get the Stockscreener App
220.04
0.02%
-0.04
After Hours:
220.14
0.10
+0.05%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $220.04, with a volume of 6.54M.
It is down -0.02% in the last 24 hours and down -1.47% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$220.08
Open:
$221.19
24h Volume:
6.54M
Relative Volume:
1.16
Market Cap:
$388.90B
Revenue:
$59.64B
Net Income/Loss:
$2.36B
P/E Ratio:
166.03
EPS:
1.3253
Net Cash Flow:
$19.68B
1W Performance:
-0.06%
1M Performance:
-1.47%
6M Performance:
+14.34%
1Y Performance:
+25.62%
1-Day Range:
$218.39
$222.49
1-Week Range:
$218.39
$237.04
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
220.04 | 388.97B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
LLY
Lilly Eli Co
|
1,081.00 | 951.91B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
209.72 | 492.44B | 92.15B | 25.12B | 20.46B | 10.36 |
|
NVS
Novartis Ag Adr
|
141.82 | 271.59B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
109.19 | 274.34B | 63.90B | 19.05B | 13.05B | 7.5596 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie Puts Up $650M to Join Emerging But Crowded Area of Cancer Drug R&D - MedCity News
AbbVie to cut drug prices, pledges $100 billion for research - marketscreener.com
Trump administration strikes deal with AbbVie to cut costs of certain drugs - news8000.com
Abbvie, US reach agreement to cut drug prices - Reuters
AbbVie (ABBV) Commits to Boosting U.S. Healthcare and Innovation - GuruFocus
Abbvie reaches deal with Trump admin to cut drug prices, invest $100 bln in US By Investing.com - Investing.com
AbbVie strikes deal with Trump administration on drug pricing By Investing.com - Investing.com Canada
AbbVie announces voluntary agreement with the Trump administration - TipRanks
Millions of Americans to see lower drug costs in new AbbVie–Trump pact - Stock Titan
AbbVie Becomes Latest To License PD-1/VEGF Bispecific In Growing Field - Citeline News & Insights
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B - Stocktwits
Chicago's AbbVie to acquire Tempe medical device manufacturing facility - The Business Journals
Key facts: AbbVie partners with RemeGen; acquires West Pharma rights - TradingView — Track All Markets
AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy - TechStock²
AbbVie inks $5.6 billion oncology deal with Chinese pharma - Crain's Chicago Business
AbbVie punts up to ~$5 billion on RemeGen bispecific antibody - The Pharma Letter
JPM26: AbbVie and RemeGen kick off deals with $5.6bn oncology agreement - Yahoo Finance
AbbVie partners with China's RemeGen on experimental tumor treatment - Reuters
Leerink Partners Adjusts AbbVie Price Target to $245 From $243, Maintains Outperform Rating - marketscreener.com
Analyst recommendations: Exxon Mobil, AbbVie, Eli Lilly, JD Sports… - marketscreener.com
AbbVie (ABBV) Secures Global Rights to RemeGen's RC148 - GuruFocus
AbbVie (ABBV) Partners with RemeGen for Cancer Therapy Developme - GuruFocus
AbbVie Inc. (NYSE : ABBV) entered into a definitive agreement to acquire Device manufacturing facility in Tempe, Arizona from West Pharmaceutical Services, Inc. (NYSE - marketscreener.com
AbbVie, RemeGen partner on experimental solid tumor treatment - The Mighty 790 KFGO
AbbVie Down 3% in a Month: Why Holding the Stock Still Makes Sense - Yahoo Finance
AbbVie and RemeGen partner on novel cancer bispecific antibody By Investing.com - Investing.com Canada
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors - Investing News Network
AbbVie licenses cancer drug from RemeGen for $650 million upfront - StreetInsider
New cancer antibody deal brings $650M push against advanced solid tumors - Stock Titan
AbbVie (ABBV) Expands with $112.5M Acquisition from West Pharmac - GuruFocus
AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States - Investing News Network
West to sell SmartDose 3.5mL system to AbbVie for $112.5 million - Investing.com India
AbbVie to acquire West Pharmaceutical’s Arizona facility for $175 million By Investing.com - Investing.com Canada
AbbVie to Acquire Drug Delivery System, Arizona Manufacturing Facility from West Pharma - marketscreener.com
West Pharmaceutical (WST) Sells Arizona Facility to AbbVie for E - GuruFocus
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations - Yahoo Finance
AbbVie to buy Arizona manufacturing facility from West Pharmaceutical (WST:NYSE) - Seeking Alpha
Drugmaker bringing 200 jobs to Arizona plant for next-gen medicines - Stock Titan
Insider Sell: How does AbbVie Inc compare to its peersEarnings Trend Report & Accurate Intraday Trade Tips - baoquankhu1.vn
Analyst Downgrade: Will AbbVie Inc announce a stock splitQuarterly Market Review & High Win Rate Trade Alerts - baoquankhu1.vn
Technical Analysis of AbbVie, Inc. CDR (CAD Hedged) (TSX:ABBV) - TradingView — Track All Markets
AbbVie stock heads into JPM Healthcare week as $30B deal talk creeps back - TechStock²
Erasca Stocks Surge Amid Merck Negotiations and AbbVie Interest - timothysykes.com
AbbVie Inc. (ABBV) Gets Downgraded to Peer Perform From Outperform by Wolfe Research - Finviz
AbbVie stock slips into weekend after $1.3 billion charge resets guidance; JPM conference looms - TechStock²
AbbVie Inc.: How a Humira Giant Is Rebuilding Its Pipeline for the Next Decade - AD HOC NEWS
Revolution Medicines Soars Amid AbbVie Acquisition Talks - StocksToTrade
AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next - TechStock²
J&J Joins Trump Administration’s MFN Pricing Initiative - Citeline News & Insights
What Catalysts Could Shift AbbVie’s Story As Analysts Rework Targets And Drug Expectations - Yahoo Finance
AbbVie Expands Bid to Block Qulipta Copies With Two Patent Suits - Bloomberg Law News
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.61%
1.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):